Gilead Sciences CEO Daniel O'Day on the collaboration with biotech firm Galapagos

Gilead Sciences is deepening its ties with biotech firm Galapagos with a new $5 billion investment. Daniel O'Day, CEO of Gilead Sciences, joins CNBC's Meg Tirrell to discuss.
04:34
Mon, Jul 15 20199:12 AM EST